Findings

What do systematic reviews say?

7 questions · 7 findings · 1 reviews · Headline outcomes only

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 1 · 14.3%Low 4 · 57.1%Moderate 2 · 28.6%High 0 · 0%

Migraine frequency Number of attacks · adults with Raynaud's phenomenon (primary or secondary)

1 finding from 1 review

Phosphodiesterase 5 inhibitors (PDE5i) for the treatment of Raynaud's phenomenon 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
Low

Duration of attacks per day (minutes) · adults with Raynaud's phenomenon (primary or secondary)

1 finding from 1 review

Phosphodiesterase 5 inhibitors (PDE5i) for the treatment of Raynaud's phenomenon 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
Low

Severity of Raynaud's attack · adults with Raynaud's phenomenon (primary or secondary)

1 finding from 1 review

Phosphodiesterase 5 inhibitors (PDE5i) for the treatment of Raynaud's phenomenon 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
Very low

Patient‐reported pain intensity or pain relief (VAS, NRS or categorical scale) · adults with Raynaud's phenomenon (primary or secondary)

1 finding from 1 review

Phosphodiesterase 5 inhibitors (PDE5i) for the treatment of Raynaud's phenomenon 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
Low

Patient global · adults with Raynaud's phenomenon (primary or secondary)

1 finding from 1 review

Phosphodiesterase 5 inhibitors (PDE5i) for the treatment of Raynaud's phenomenon 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
Low

Withdrawals due to adverse events · adults with Raynaud's phenomenon (primary or secondary)

1 finding from 1 review

Phosphodiesterase 5 inhibitors (PDE5i) for the treatment of Raynaud's phenomenon 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
Moderate

Serious adverse events · adults with Raynaud's phenomenon (primary or secondary)

1 finding from 1 review

Phosphodiesterase 5 inhibitors (PDE5i) for the treatment of Raynaud's phenomenon 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
Moderate